Top 5 Stocks to Buy Now
→ SpaceX IPO hides a much bigger story (From Weiss Ratings) (Ad)tc pixel Free RVPH Stock Alerts

Reviva Pharmaceuticals (RVPH) Competitors

Reviva Pharmaceuticals logo
$0.67 -0.03 (-3.60%)
As of 06/24/2026 03:48 PM Eastern
Compare

RVPH vs. GRDX, ADXS, ZYBT, BGM, and GRML

Should you buy Reviva Pharmaceuticals stock or one of its competitors? MarketBeat compares Reviva Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Reviva Pharmaceuticals include Entero Therapeutics (GRDX), Ayala Pharmaceuticals (ADXS), Zhengye Biotechnology (ZYBT), BGM Group (BGM), and Greenland Mines Ltd. Common Stock (GRML). These companies are all part of the "pharmaceutical products" industry.

How does Reviva Pharmaceuticals compare to Entero Therapeutics?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Entero Therapeutics (NASDAQ:GRDX) are both small-cap pharmaceutical products companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, earnings, analyst recommendations, institutional ownership, dividends, risk, valuation and profitability.

63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. Comparatively, 12.3% of Entero Therapeutics shares are owned by institutional investors. 8.9% of Reviva Pharmaceuticals shares are owned by insiders. Comparatively, 0.8% of Entero Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Entero Therapeutics has higher revenue and earnings than Reviva Pharmaceuticals. Entero Therapeutics is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$4.06N/A
Entero Therapeutics$40K734.83-$6.39M-$1.88N/A

Reviva Pharmaceuticals presently has a consensus target price of $66.67, indicating a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts plainly believe Reviva Pharmaceuticals is more favorable than Entero Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Entero Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Entero Therapeutics' return on equity of -49.81% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
Entero Therapeutics N/A -49.81%-11.02%

Reviva Pharmaceuticals has a beta of 0.57, suggesting that its stock price is 43% less volatile than the broader market. Comparatively, Entero Therapeutics has a beta of 1.8, suggesting that its stock price is 80% more volatile than the broader market.

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than Entero Therapeutics. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for Entero Therapeutics. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Entero Therapeutics' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Reviva Pharmaceuticals Neutral
Entero Therapeutics Neutral

Summary

Reviva Pharmaceuticals beats Entero Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Ayala Pharmaceuticals?

Reviva Pharmaceuticals (NASDAQ:RVPH) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings.

Ayala Pharmaceuticals' return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Reviva PharmaceuticalsN/A -391.58% -119.08%
Ayala Pharmaceuticals N/A N/A N/A

Reviva Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market. Comparatively, Ayala Pharmaceuticals has a beta of 1.75, meaning that its share price is 75% more volatile than the broader market.

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than Ayala Pharmaceuticals. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for Ayala Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Ayala Pharmaceuticals' score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
Reviva Pharmaceuticals Neutral
Ayala Pharmaceuticals Neutral

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Reviva Pharmaceuticals has higher earnings, but lower revenue than Ayala Pharmaceuticals. Reviva Pharmaceuticals is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Reviva PharmaceuticalsN/AN/A-$19.86M-$4.06N/A
Ayala Pharmaceuticals$3.24M11.05-$48.07M-$5.02N/A

Reviva Pharmaceuticals currently has a consensus price target of $66.67, indicating a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts clearly believe Reviva Pharmaceuticals is more favorable than Ayala Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50
Ayala Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Reviva Pharmaceuticals beats Ayala Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Zhengye Biotechnology?

Zhengye Biotechnology (NASDAQ:ZYBT) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations, institutional ownership and media sentiment.

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 8.9% of Reviva Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Zhengye Biotechnology's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Zhengye BiotechnologyN/A N/A N/A
Reviva Pharmaceuticals N/A -391.58%-119.08%

Zhengye Biotechnology has a beta of -2.4, meaning that its share price is 340% less volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than Zhengye Biotechnology. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for Zhengye Biotechnology. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Zhengye Biotechnology's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
Zhengye Biotechnology Neutral
Reviva Pharmaceuticals Neutral

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Reviva Pharmaceuticals is more favorable than Zhengye Biotechnology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zhengye Biotechnology
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

Zhengye Biotechnology has higher revenue and earnings than Reviva Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Zhengye Biotechnology$16.64M2.20-$9.98MN/AN/A
Reviva PharmaceuticalsN/AN/A-$19.86M-$4.06N/A

Summary

Reviva Pharmaceuticals beats Zhengye Biotechnology on 8 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to BGM Group?

BGM Group (NASDAQ:BGM) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, earnings, risk, media sentiment, valuation, analyst recommendations and institutional ownership.

63.2% of Reviva Pharmaceuticals shares are held by institutional investors. 58.7% of BGM Group shares are held by insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

BGM Group has a beta of 1.81, meaning that its stock price is 81% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, meaning that its stock price is 43% less volatile than the broader market.

Reviva Pharmaceuticals has a consensus price target of $66.67, indicating a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than BGM Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BGM Group
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

BGM Group's return on equity of 0.00% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
BGM GroupN/A N/A N/A
Reviva Pharmaceuticals N/A -391.58%-119.08%

In the previous week, Reviva Pharmaceuticals had 3 more articles in the media than BGM Group. MarketBeat recorded 3 mentions for Reviva Pharmaceuticals and 0 mentions for BGM Group. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat BGM Group's score of 0.00 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company Overall Sentiment
BGM Group Neutral
Reviva Pharmaceuticals Neutral

BGM Group has higher revenue and earnings than Reviva Pharmaceuticals.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BGM Group$25.10M1.32-$1.44MN/AN/A
Reviva PharmaceuticalsN/AN/A-$19.86M-$4.06N/A

Summary

BGM Group and Reviva Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Reviva Pharmaceuticals compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, media sentiment, analyst recommendations, earnings, risk and institutional ownership.

In the previous week, Greenland Mines Ltd. Common Stock and Greenland Mines Ltd. Common Stock both had 3 articles in the media. Reviva Pharmaceuticals' average media sentiment score of 0.42 beat Greenland Mines Ltd. Common Stock's score of 0.13 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Greenland Mines Ltd. Common Stock
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Reviva Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Reviva Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Greenland Mines Ltd. Common StockN/A -109.40% -98.80%
Reviva Pharmaceuticals N/A -391.58%-119.08%

Greenland Mines Ltd. Common Stock has a beta of 6.94, indicating that its share price is 594% more volatile than the broader market. Comparatively, Reviva Pharmaceuticals has a beta of 0.57, indicating that its share price is 43% less volatile than the broader market.

Reviva Pharmaceuticals has a consensus target price of $66.67, suggesting a potential upside of 9,850.25%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Greenland Mines Ltd. Common Stock.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Greenland Mines Ltd. Common Stock
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Reviva Pharmaceuticals
1 Sell rating(s)
2 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.50

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by company insiders. Comparatively, 8.9% of Reviva Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Greenland Mines Ltd. Common Stock is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Greenland Mines Ltd. Common StockN/AN/A-$10.55M-$0.32N/A
Reviva PharmaceuticalsN/AN/A-$19.86M-$4.06N/A

Summary

Greenland Mines Ltd. Common Stock and Reviva Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

Get Reviva Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RVPH vs. The Competition

Export
MetricReviva PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$8.78M$2.99B$6.74B$12.32B
Dividend YieldN/A1.78%2.68%5.88%
P/E Ratio-0.1718.6525.3723.95
Price / SalesN/A341.96530.17107.90
Price / CashN/A56.6445.2953.76
Price / Book0.454.1410.766.41
Net Income-$19.86M$64.45M$3.56B$337.14M
7 Day Performance9.84%1.22%0.99%-1.06%
1 Month Performance62.23%0.95%0.79%0.49%
1 Year Performance-95.61%25.22%30.25%28.43%

Reviva Pharmaceuticals Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RVPH
Reviva Pharmaceuticals
3.0989 of 5 stars		$0.67
-3.6%		$66.67
+9,850.2%		-95.8%$8.78MN/AN/A5
GRDX
Entero Therapeutics
0.1974 of 5 stars		$4.86
-10.0%		N/AN/A$35.93M$40KN/A9
ADXS
Ayala Pharmaceuticals
N/A$0.60
flat		N/AN/A$35.79M$3.24MN/A20
ZYBT
Zhengye Biotechnology
N/A$0.72
-4.3%		N/A-89.8%$35.54M$16.64MN/A278
BGM
BGM Group
0.4449 of 5 stars		$0.33
-9.1%		N/A-97.4%$35.49M$25.10MN/A298

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RVPH) was last updated on 6/25/2026 by MarketBeat.com Staff.
From Our Partners
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
The roadshow starts Monday. This stock isn't ready.
The SpaceX roadshow kicks off June 8. Goldman Sachs, the lead underwriter, will present the full S-1 to the wo...
Behind the Markets | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
Trump just signed it
A recent policy development is drawing attention from income-focused investors. According to one analyst, c...
Investors Alley | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
SpaceX is chump change compared to Elon’s $20T ‘iPhone’
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel